Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 5/20 | 0.36 |
| ▸ | SAT1 | P21673 | 3/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15846169 | 0.95 | CYP2C19 (0.40) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL4860864 | 0.89 | CYP2C19 (0.31) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| Diethylamine SCHEMBL21409758 | 0.85 | TSHR (0.37) | CYP2C19MEN1KMT2ACYP1A2TSHR | |
| SCHEMBL1846398 | 0.84 | ALDH1A1 (0.43) | CYP2C19MEN1KMT2ACYP1A2TSHR | |
| SCHEMBL636778 | 0.83 | CYP2C19 (0.39) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL636776 | 0.83 | CYP2C19 (0.39) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| Diethylamine SCHEMBL5673024 | 0.81 | GRIK1 (0.33) | — | |
| SCHEMBL3858507 | 0.81 | KISS1R (0.34) | — | |
| SCHEMBL18579303 | 0.81 | KDM4E (0.35) | CYP2C19MEN1KMT2ACYP1A2TSHR | |
| SCHEMBL10941100 | 0.80 | TP53BP1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11479710-B2 | Substituted alkanolamine scale inhibitor | HALLIBURTON ENERGY SERVICES, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| US-20220186105-A1 | SUBSTITUTED ALKANOLAMINE SCALE INHIBITOR | HALLIBURTON ENERGY SERVICES, INC. | 2022-06-16 | — | — | US | disclosed |
| US-20220169545-A1 | METHODS AND COMPOSITIONS FOR TREATING PRODUCED WATER | STERLING SPECIALTY CHEMICALS HOLDING UK LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
| CN-114174446-A | Primer coatings for inkjet and liquid-phase electrophotographic printing | 米切尔曼公司 | 2022-03-11 | — | — | CN | disclosed |
| US-10772822-B2 | Molecularly imprinted polymers and their use as antidandruff agents | L'OREAL (FR) | 2020-09-15 | — | — | US | disclosed |
| EP-2938641-B1 | MOLECULARLY IMPRINTED POLYMERS AND THEIR USE AS ANTIDANDRUFF AGENTS | ORÉAL L (FR) | 2016-08-24 | — | — | EP | disclosed |
| US-20150342859-A1 | MOLECULARLY IMPRINTED POLYMERS AND THEIR USE AS ANTIDANDRUFF AGENTS | L'OREAL (FR) | 2015-12-03 | — | — | US | disclosed |
| EP-2938641-A1 | MOLECULARLY IMPRINTED POLYMERS AND THEIR USE AS ANTIDANDRUFF AGENTS | L'Oréal (FR) | 2015-11-04 | — | — | EP | disclosed |
| WO-2014102206-A1 | MOLECULARLY IMPRINTED POLYMERS AND THEIR USE AS ANTIDANDRUFF AGENTS | L'OREAL (FR) | 2014-07-03 | — | — | WO | disclosed |
| WO-2012113723-A2 | COMPOSITION FOR DYEING KERATIN FIBRES COMPRISING A DIRECT DYE BEARING A DISULFIDE/THIOL FUNCTION, A NON-CELLULOSE-BASED THICKENING POLYMER, AN ALKALINE AGENT AND A REDUCING AGENT | L'OREAL (FR) | 2012-08-30 | — | — | WO | disclosed |
| EP-1458933-A1 | METHOD FOR PRODUCING PAPER, PAPERBOARD AND CARDBOARD | BASF AKTIENGESELLSCHAFT (DE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004035668-A2 | SUPERABSORBING FOAM, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003052205-A1 | METHOD FOR PRODUCING PAPER, PAPERBOARD AND CARDBOARD | BASF AKTIENGESELLSCHAFT (DE) | 2003-06-26 | — | — | WO | disclosed |
| EP-1287104-A1 | USE OF CATIONICALLY MODIFIED, PARTICLE-SHAPED, HYDROPHOBIC POLYMERS AS ADDITION AGENTS IN TEXTILE RINSING OR CARE PRODUCTS AND AS ADDITION AGENTS IN DETERGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001094516-A1 | USE OF CATIONICALLY MODIFIED, PARTICLE-SHAPED, HYDROPHOBIC POLYMERS AS ADDITION AGENTS IN TEXTILE RINSING OR CARE PRODUCTS AND AS ADDITION AGENTS IN DETERGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-12-13 | — | — | WO | disclosed |
| EP-0929285-A2 | USE OF WATER-SOLUBLE COPOLYMERS AS ACTIVE INGREDIENTS IN COSMETICS | BASF AKTIENGESELLSCHAFT (DE) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998014164-A2 | USE OF WATER-SOLUBLE COPOLYMERS AS ACTIVE INGREDIENTS IN COSMETICS | BASF AKTIENGESELLSCHAFT (DE) | 1998-04-09 | — | — | WO | disclosed |
| WO-1995002674-A1 | PREVENTION OF THE FORMATION OF FILMY DEPOSITS AFTER RINSING IN NON-DOMESTIC CLEANING PROCESSES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1995-01-26 | — | — | WO | disclosed |
| EP-0277580-A2 | Modification of the wet fastness of sulphur dyeings | CASSELLA Aktiengesellschaft (DE) | 1988-08-10 | — | — | EP | disclosed |
| EP-0249380-A2 | Shade enhancing agent | Kao Corporation (JP) | 1987-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772822-B2 | Molecularly imprinted polymers and their use as antidandruff agents | DNMT1, POLR1C, ETF1 | CYP2C19 177/4885MEN1 599/4885GLA 4396/4885 |
| US-20150342859-A1 | MOLECULARLY IMPRINTED POLYMERS AND THEIR USE AS ANTIDANDRUFF AGENTS | DNMT1, POLR1C, ETF1 | CYP2C19 177/4885MEN1 599/4885GLA 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.